| Drug Name |
Teriflunomide |
| Drug ID |
BADD_D02165 |
| Description |
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. |
| Indications and Usage |
Used in the treatment of relapsing forms of multiple sclerosis (MS). |
| Marketing Status |
Prescription |
| ATC Code |
L04AA31 |
| DrugBank ID |
DB08880
|
| KEGG ID |
D10172
|
| MeSH ID |
C527525
|
| PubChem ID |
54684141
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
69238-1303; 65727-058; 12579-186; 69238-1304; 66499-0059; 59285-001; 69539-032; 47621-049; 17337-0070; 69037-0016; 58468-0211; 63850-8081; 12579-185; 46708-888; 12579-191; 53747-061; 69539-033; 14501-0086; 58468-0210; 59651-036; 66039-916; 0115-1565; 12579-190 |
| Synonyms |
teriflunomide | (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | (2Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide | RS 61980 | Aubagio | HMR1726 | HMR-1726 | A 771726 | A 1726 | A771726 | A-771726 | A77 1726 |
